The use of amphotericin B lipid complex

Franklin, Ian M.; Mehta, J. N.; Root, Thomas E.

doi:10.1093/jac/39.2.288

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid preparations of amphotericin are expensive and, as such, in most centres usage is confined to treatment failures of conventional amphotericin B (Franklin et al, 1997). The value of these agents was underlined in this study.…”

Section: Discussionmentioning

confidence: 90%

A comparative analysis of lipid‐complexed and liposomal amphotericin B preparations in haematological oncology

et al. 1998

View full text Add to dashboard Cite

No comparative clinical information on the properties of lipid-associated amphotericin preparations is presently available. In this single-centre retrospective analysis over a 5-year period the indications, efficacy and toxicity of true liposomal amphotericin (AmBisome) were compared with a lipid complexed preparation (Abelcet). In a novel approach APACHE III scores were used in addition to neutrophil counts, disease status and additional immunosuppression to accurately assess the severity of illness in both groups and enable valid comparison. Overall, AmBisome at a median dose of 1.9 mg/kg/d was found to have similar clinical outcome to Abelcet at a median dose of 4.8 mg/kg/d. Nephrotoxicity and electrolyte abnormalities were similar in both groups. Rigors and febrile episodes were more common with Abelcet. Prospective randomized comparative trials are required to clarify the optimum dosages and therapeutic and economic issues associated with these agents.

show abstract

Section: Discussionmentioning

confidence: 90%

A comparative analysis of lipid‐complexed and liposomal amphotericin B preparations in haematological oncology

et al. 1998

View full text Add to dashboard Cite

show abstract

“…In animal models, ABLC has been shown to be at least as effective as amphotericin B and substantially less toxic. The drug is indicated for the treatment of severe invasive candidiasis and as second‐line treatment of invasive aspergillosis, cryptococcosis in HIV patients and miscellaneous fungal infections ( Franklin et al , 1997 ; Mehta et al , 1997 ; Oravcocá et al , 1995 ). The drug appears to be cleared rapidly from the serum.…”

Section: Specific Fungal Infections In Bone Marrow Transplant Recipientsmentioning

confidence: 99%

Antifungal Therapy in ‘Bone Marrow Failure’

Richardson

Kokki

1998

Br J Haematol

View full text Add to dashboard Cite

“…AmB-lipid complex (Abelcet ® ): Similar to liposomal AmB, AmB-lipid complex has also been shown to be less toxic and at least as effective as cAmB [42][43][44]. The recommended dosage is 5 mg/kg for a minimum of 2 weeks.…”

Section: Aspergillosismentioning

confidence: 99%

Systemic Fungal Infections in Patients with Hematologic Malignancies: Indications and Limitations of the Antifungal Armamentarium

Böhme

Karthaus

1999

Chemotherapy

View full text Add to dashboard Cite

The rates of fungal infections have increased substantially in Europe as well as in North America. Most frequently Aspergillus spp. and Candida spp. are isolated. Despite the recent introduction of new azoles and lipid-based formulations of amphotericin B, there are relatively few randomized, controlled studies on the use of antifungal drugs in patients with hematological malignancies and invasive fungal infections. Conventional amphotericin B is considered the gold standard for the treatment of invasive fungal infections; however, adverse events limit conventional amphotericin B treatment. The newer azoles, fluconazole and itraconazole, are well tolerated; however, fluconazole has no activity against Aspergillus spp. An additional serious problem is the emerging resistance of nonalbicans Candida spp. to fluconazole. In this situation, lipid formulations of amphotericin B seem to be attractive, since the use of these drugs has been shown to be safe and effective. Considerably higher medical costs limit broader application of lipid formulations of amphotericin B. Because of the rapidly increasing incidence of serious fungal infections, we have reviewed current strategies and the role of newer antifungal drugs for the treatment of deep-organ infections.

show abstract

The use of amphotericin B lipid complex

Cited by 5 publications

References 0 publications

A comparative analysis of lipid‐complexed and liposomal amphotericin B preparations in haematological oncology

A comparative analysis of lipid‐complexed and liposomal amphotericin B preparations in haematological oncology

Antifungal Therapy in ‘Bone Marrow Failure’

Systemic Fungal Infections in Patients with Hematologic Malignancies: Indications and Limitations of the Antifungal Armamentarium

Contact Info

Product

Resources

About